Skip to main content
Fig. 6 | Experimental Hematology & Oncology

Fig. 6

From: Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Fig. 6

Mitigation of cytokine release by blinatumomab step-dosing. a Mean peak serum concentrations (Cmax) ± SD of cytokines IL-2, IL-6, IL-10, TNF-α, IFN-γ and mean peak body temperature (Tmax) ± SD in patients who received blinatumomab doses of either 5 or 15 µg/m2/day as first dose during treatment week 1, or 15 µg/m2/day as second dose in week 2. b Cmax of IL-6 and Tmax in patients receiving different blinatumomab doses during week 1 or 2. Orange 15 µg/m2/day flat dose; black 5 µg/m2/day first dose in cycle 1; blue 15 µg/m2/day second dose in cycle 1. Corresponding patient numbers are shown in Additional file 6

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us